31Volume 15 I Nu mber 7 I 2007 I MEDICINE UPDATEhimalaya updatebiochemical tests were done at theend of 1st, 2nd and 3rd month oftreatment. The predefined primaryendpoints were clinical andlaboratory evidence of normalfunctioning of liver.In the Atorvastatin alone group,there was a significant increase(p<0.01) in the mean values of SGPTfrom 45.87 ± 4.98 to 102.70 ± 12.05,SGOT from 42.70 ± 4.74 to 98.87 ±12.35, and total bilirubin from 0.800 ±0.026 to 1.022 ± 0.077 after 3 months,whereas no such increase in SGPT,SGOT and total bilirubin wasobserved in the group receivingLiv.52 DS tablet + Atorvastatin, after3 months.There were no significantdifferences between the groups interms of physical examination andsubjective signs after 3 months oftreatment. Therefore, it may beconcluded that Liv.52 DS tablet hashepatoprotective effect against statin-induced liver damage.INTRODUCTIONLipids are important biomolecules.Cholesterol, for example, is anessential component of the humancell membrane and a precursor forsteroid hormones and bile acids.Triglycerides also play an importantrole in transferring energy from foodinto body cells. Elevation of differentforms of lipids in the bloodstream, acondition generally termedhyperlipidemia, causes a constanthealth problem. Because lipids arecarried in the bloodstream,Dr. JKL DasAssociate Professor,Department of Medicine,Patna Medical College,Patna, India.Dr. S.R. Prasad*,Medical Advisor,Dr. S.K. Mitra,Executive Director,R&D Center,The Himalaya Drug Company,Bangalore-562 123, India.ABSTRACTThe present study was planned toevaluate Liv.52 DS tablet as ahepatoprotective agent inprophylaxis with statin therapy.HMG-CoA reductase inhibitors(statins) are the most commonlyprescribed classes of medications fordyslipidemia...
